| Metabolomic signature of brain cancer R Pandey, L Caflisch, A Lodi, AJ Brenner, S Tiziani Molecular Carcinogenesis 56 (11), 2355-2371, 2017 | 108 | 2017 |
| The C. elegans male exercises directional control during mating through cholinergic regulation of sex-shared command interneurons AL Sherlekar, A Janssen, MS Siehr, PK Koo, L Caflisch, M Boggess, ... PloS one 8 (4), e60597, 2013 | 42 | 2013 |
| Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study A Brenner, R Zuniga, JD Sun, J Floyd, CP Hart, S Kroll, L Fichtel, ... Neuro-oncology 20 (9), 1231-1239, 2018 | 29 | 2018 |
| Phase II investigation of TVB-2640 (denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma W Kelly, AE Diaz Duque, J Michalek, B Konkel, L Caflisch, Y Chen, ... Clinical Cancer Research 29 (13), 2419-2425, 2023 | 10 | 2023 |
| Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone. B Konkel, LD Caflisch, AE Diaz Duque, J Michalek, Q Liu, AJ Brenner Journal of Clinical Oncology 37 (15_suppl), 2064-2064, 2019 | 10 | 2019 |
| 368MO Fatty acid synthase inhibitor TVB-2640 with bevacizumab in recurrent glioblastoma W Kelly, J Michalek, AED Duque, V Madhusudanannair, L Caflisch, ... Annals of Oncology 31, S399, 2020 | 4 | 2020 |
| ACTR-25. updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with avastin versus … B Konkel, L Caflisch, AED Duque, AJ Brenner Neuro-Oncology 20 (Suppl 6), vi16, 2018 | 4 | 2018 |
| ACTR-45. FATTY ACID SYNTHASE INHIBITOR TVB-2640 INCREASES PROGRESSION FREE SURVIVAL IN RECURRENT GBM B Konkel, J Michalek, ED Duque, Q Liu, L Caflisch, V Madhu, A Brenner Neuro-Oncology 21 (Suppl 6), vi23, 2019 | 1 | 2019 |
| Metabolic adaptations of glioblastoma in hypoxia is mediated by acox-1 A Bhattacharya, L Caflisch, H Balinda, A Lodi, M Zhou, M Li, J Chiou, ... Cancer Research 84 (6_Supplement), 4422-4422, 2024 | | 2024 |
| HYPOXIA-INDUCED METABOLIC ADAPTATIONS THROUGH ACOX-1 IN GLIOBLASTOMA A Bhattacharya, L Caflisch, H Balinda, A Boyer, A Lodi, M Zhou, M Li, ... NEURO-ONCOLOGY 24, 25-26, 2022 | | 2022 |
| The Role of Peroxisomal Fatty Acid Oxidation in Adaptation to Chronic Hypoxia During Anti-Angiogenic Therapy in Glioblastoma L Caflisch The University of Texas Health Science Center at San Antonio, 2020 | | 2020 |
| CBMT-39. TARGETING METABOLIC PATHWAYS IN HYPOXIA FOR GLIOBLASTOMA A Gruslova, A Lodi, M Li, M Zhou, M Garcia, S Tiziani, A Brenner, ... Neuro-Oncology 21 (Suppl 6), vi41, 2019 | | 2019 |
| CBMT-11. PEROXISOMAL FATTY ACID OXIDATION IN GLIOBLASTOMA DURING HYPOXIA L Caflisch, A Gruslova, M Garcia, A Lodi, S Tiziani, AJ Brenner Neuro-Oncology 20 (Suppl 6), vi34, 2018 | | 2018 |
| FASN inhibition as a potential treatment to prevent metabolic adaptation in GBM A Gruslova, AD Duque, L Caflisch, S Tiziani, A Lodi, A Brenner SNO 2017 Annual Meeting, 2017 | | 2017 |
| DDIS-20. FASN INHIBITION AS A POTENTIAL TREATMENT TO PREVENT METABOLIC ADAPTATION IN GBM A Gruslova, AD Duque, L Caflisch, S Tiziani, A Lodi, A Brenner Neuro-oncology, 2017 | | 2017 |
| Metb-09. Metabolic Adaptation To Chronic Hypoxia In Glioblastoma Cells L Caflisch, A Lodi, A Gruslova, D Cavazos, M Garcia, S Tiziani, A Brenner Neuro-oncology 19 (Suppl 6), vi130, 2017 | | 2017 |
| METB-03TARGETING CANCER CELL METABOLISM IN GLIOBLASTOMA D Cavazos, L Caflisch, A Gruslova, M Garcia, A Brenner Neuro-oncology 17 (Suppl 5), v135, 2015 | | 2015 |
| Predicting and modulating aging from cell cycle phenotypes M Polymenis, C He, S Tsuchiyama, Q Ngyen, L Caflisch, B Kennedy YEAST 30, 94-94, 2013 | | 2013 |
| Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab B Konkel, L Caflisch, ED Duque, J Michalek, Q Liu, A Brenner | | |
